연구동향 분석

Development of Peptide Vaccine Targeting Heat Shock Protein 90 to Overcome Resistance to HER2-Targeted Drugs in Breast Cancer 유방암에서 HER2 표적 약물에 대한 내성을 극복하기 위해 HSP90을 표적 하는 펩타이드 백신의 개발

강진호 2020년

논문상세정보
인용/피인용
' Development of Peptide Vaccine Targeting Heat Shock Protein 90 to Overcome Resistance to HER2-Targeted Drugs in Breast Cancer 유방암에서 HER2 표적 약물에 대한 내성을 극복하기 위해 HSP90을 표적 하는 펩타이드 백신의 개발' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • HER2 positive breast cancer
  • Heat Shock Protein 90
  • Immunologic strategy
  • peptidevaccine
  • t cells
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
47 0

0.0%

' Development of Peptide Vaccine Targeting Heat Shock Protein 90 to Overcome Resistance to HER2-Targeted Drugs in Breast Cancer 유방암에서 HER2 표적 약물에 대한 내성을 극복하기 위해 HSP90을 표적 하는 펩타이드 백신의 개발' 의 참고문헌

  • 젊은 한국인 유방 암 환자에서 BRCA1/2 돌연변이와 호르몬 수용체, HER2 상태에 관 한 연구. A Study on BRCA1/2 Mutations
    김용호 김은석 이동화 진소영 최두호 Hormone Status and HER2 Status in Korean Women with Early-onset Breast Cancer 대한방사선종양학회지 26(1):65-73 [2008]
  • Vaccines for established cancer : overcoming the challenges posed by immune evasion
    16 ( 4 ) :219-233 . [2016]
  • Type I interferons in anticancer immunity
    15 ( 7 ) :405- 414 . [2015]
  • Type I interferon response and innate immune sensing of cancer
    34 ( 2 ) :67-73 [2013]
  • Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2 : a phase I/II study .
    12 ( 12 ) :1005-1016 . [2005]
  • Treatment of HER2-positive breastCancer :Current status and future perspectives .
    9 ( 1 ) :16-32 . [2011]
  • Towards personalized , tumour-specific , therapeutic vaccines for cancer
    18 ( 3 ) :168-182 . [2018]
  • The three-dimensional structure of peptide-MHC complexes
    [1995]
  • The role of overexpressed HER2 in transformation .
    12 Suppl 1 : S9-13 . [2001]
  • The role of HER2 in cancer therapy and targeted drug delivery
    146 ( 3 ) :264-275 [2010]
  • The basic biology of HER2
    12 Suppl 1 : S3-8 [2001]
  • The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells
    4 ( 7 ) . [2019]
  • Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells
    10 ( 2 ) :498-515 [2020]
  • Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100 .
    63 ( 10 ) :2553-2560 . [2003]
  • Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer
    17 ( 9 ) :2234- 2246 [2016]
  • TMEM203 is a binding partner and regulator of STINGmediated inflammatory signaling in macrophages
    116 ( 33 ) :16479-16488 [2019]
  • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    244 ( 4905 ) :707-712 . [1989]
  • Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers : focus on new data from clinical trials
    [2014]
  • Safety , activity , and immuneCorrelates of anti-pd-1 antibody inCancer
    366 ( 26 ) :2443-2454 [2012]
  • STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors
    41 ( 5 ) :830-842 . [2014]
  • STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
    41 ( 5 ) :843-852 . [2014]
  • STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice
    immunotherapy : CII 64 ( 8 ) :1057-1066 . [2015]
  • Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
    74 ( 5 ) :929-937 [1993]
  • Prognostic and predictive value of HER2 extracellular domain in metastatic breastCancer treated with lapatinib and paclitaxel in a randomized phase III study
    27 ( 33 ) :5552-5558 [2009]
  • Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -a translational project in the neoadjuvant GeparQuinto trial
    107 ( 6 ) :956-960 . [2012]
  • Phase I study of 17-allylamino-17 demethoxygeldanamycin , gemcitabine and/or cisplatin in patients with refractory solid tumors
    29 ( 3 ) :473-480 . [2011]
  • Phase I pharmacokinetic-pharmacodynamic study of 17- ( allylamino ) -17-demethoxygeldanamycin ( 17AAG , NSC 330507 ) , a novel inhibitor of heat shock protein 90 , in patients with refractory advanced cancers
    11 ( 9 ) :3385-3391 [2005]
  • Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino , 17-demethoxygeldanamycin in patients with advanced malignancies
    23 ( 18 ) :4152-4161 [2005]
  • Peptide-based vaccines in breast cancer
    [2004]
  • PTEN activationContributes to tumor inhibition by trastuzumab , and loss of PTEN predicts trastuzumab resistance in patients
    6 ( 2 ) :117-127 [2004]
  • Novel anticancer targets : revisiting ERBB2 and discovering ERBB3 .
    9 ( 7 ) :463-475 . [2009]
  • NVP-AUY922 : a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models .
    10 ( 2 ) : R33 . [2008]
  • Monitoring of serum HER2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer .
    10 ( 5 ) :1618-1624 [2004]
  • Modulation of T-cell function by type I interferon
    90 ( 5 ) :492-497 . [2012]
  • Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    68 ( 5 ) :1471-1477 [2008]
  • Maximizing the retention of antigen specific lymphocyte function after cryopreservation
    308 ( 1-2 ) :13-18 [2006]
  • Lapatinib enhances trastuzumab-mediated antibodydependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells
    34 ( 6 ) :2864-2870 . [2015]
  • Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer
    4 ( 3 ) :151 . [2014]
  • Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer
    68 ( 20 ) :8400- 8409 . [2008]
  • Insulin-like growth factor-I receptor signaling and resistance to trastuzumab ( Herceptin )
    93 ( 24 ) :1852-1857 [2001]
  • Innate and adaptive immune cells in the tumor microenvironment
    14 ( 10 ) :1014-1022 [2013]
  • Inhibitors of the HSP90 molecular chaperone : current status
    [2006]
  • Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses .
    11 ( 6 ) :2416-2426 . [2005]
  • In situ adenovirus vaccination engages T effector cells against cancer
    27 ( 31 ) :4225-4239 . [2009]
  • Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach
    20 ( 9 ) :1388-1397 [2004]
  • Immunosurveillance and Immunoediting of Lung Cancer : Current Perspectives and Challenges
    21 ( 2 ) . [2020]
  • Immunoediting of cancers may lead to epithelial to mesenchymal transition .
    177 ( 3 ) :1526-1533 . [2006]
  • Identification of new biomarkers for clinical trials of Hsp90 inhibitors
    5 ( 5 ) :1256-1264 . [2006]
  • Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library
    87 ( 3 ) :339-343 [2002]
  • IL-2 immunotoxin therapy modulates tumorassociated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice
    177 ( 1 ) :84-91 . [2006]
  • Human breast cancer : correlation of relapse and survival with amplification of the HER-2/neu oncogene
    [1987]
  • Human Breast Cancer Cells Selected for Resistance to Trastuzumab & lt ; em & gt ; In vivo & lt ; /em & gt ; Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
    13 ( 16 ) :4909 [2007]
  • High HSP90 expression is associated with decreased survival in breast cancer
    67 ( 7 ) :2932-2937 . [2007]
  • Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma : a phase II , single-arm trial
    16 ( 2 ) :274- 279 [2014]
  • HSPPC-96 : a personalised cancer vaccine
    1 ( 3 ) :539-547 . [2001]
  • HSP90 inhibition is effective in breast cancer : a phase II trial of tanespimycin ( 17-AAG ) plus trastuzumab in patients with HER2- positive metastatic breast cancer progressing on trastuzumab .
    17 ( 15 ) :5132-5139 [2011]
  • HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
    8 ( 1 ) :451 . [2017]
  • HSP90 inhibition : two-pronged exploitation of cancer dependencies .
    17 ( 5-6 ) :242-252 . [2012]
  • HSP90 and the chaperoning of cancer
    5 ( 10 ) :761-772 . [2005]
  • HER2-positive breast cancer : new therapeutic frontiers and overcoming resistance
    [2019]
  • HER2-positive advanced breast cancer : optimizing patient outcomes and opportunities for drug development
    111 ( 10 ) :1888-1898 [2014]
  • Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease .
    89 ( 22 ) :10578- 10582 [1992]
  • Expression of p95HER2 , a Truncated Form of the HER2 Receptor , and Response to Anti-HER2 Therapies in Breast Cancer
    99 ( 8 ) :628-638 [2007]
  • Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy .
    47 ( 2 ) :721-734 [2018]
  • Epitope-specific antibody levels in tuberculosis : biomarkers of protection , disease , and response to treatment
    [2014]
  • Epitope-based vaccines : an update on epitope identification , vaccine design and delivery
    15 ( 4 ) :461-470 . [2003]
  • Epitope spreading in immune-mediated diseases : implications for immunotherapy .
    2 ( 2 ) :85-95 . [2002]
  • Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients .
    3 ( 6 ) :731- 733 [2011]
  • Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce danger signals
    96 ( 3 ) :233-241 . [2006]
  • Elevated serum HER2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
    20 ( 6 ) :1467-1472 [2002]
  • Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials .
    5 ( 3 ) :326-334 . [2016]
  • EGFR over-expression and activation in high HER2 , ER negative breast cancer cell line induces trastuzumab resistance
    122 ( 3 ) :685-697 [2010]
  • Developing DNA vaccines that call to dendritic cells
    114 ( 9 ) :1241-1244 [2004]
  • Determinant spreading and the dynamics of the autoimmune T-cell repertoire
    14 ( 5 ) :203-208 . [1993]
  • Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
    206 ( 7 ) :1589-1602 . [2009]
  • Dendritic cell/peptide cancer vaccines : clinical responsiveness and epitope spreading .
    29 ( 2 ) :121-125 . [2000]
  • Dendritic Cell-Based Immunotherapy of Malignant Gliomas
    22 ( 3 ) :405-416 . [2004]
  • DNA vaccines : basic mechanism and immune responses ( Review )
    4 ( 5 ) :549-555 [1999]
  • Current patent and clinical status of stimulator of interferon genes ( STING ) agonists for cancer immunotherapy
    8 ( 4 ) :87-90 . [2019]
  • Combination of trastuzumab and tanespimycin ( 17-AAG , KOS-953 ) is safe and active in trastuzumab-refractory HER2 overexpressing breast cancer : a phase I dose-escalation study
    25 ( 34 ) :5410- 5417 [2007]
  • Clinical , Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer
    [2017]
  • Circulating HER2/erbB2/c-neu ( HER2 ) extracellular domain as a prognostic factor in patients with metastatic breast cancer : Cancer and Leukemia Group B Study 8662
    7 ( 9 ) :2703-2711 [2001]
  • Cancer vaccines : between the idea and the reality .
    3 ( 8 ) :630-641 . [2003]
  • Autoantibodies to 90 kD heat-shock protein in sera of breast cancer patients
    345 ( 8942 ) :126 [1995]
  • Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer
    18 ( 2 ) :105-116 [2017]
  • Antigenic peptide binding by class I and class II histocompatibility proteins
    2 ( 4 ) :245-251 [1994]
  • Antigen processing by autoreactive B cells promotes determinant spreading .
    2 ( 3 ) :169-175 . [2005]
  • Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy .
    82 ( 1 ) :85-87 [2000]
  • Annual hazard rates of recurrence for breast cancer after primary therapy
    14 ( 10 ) :2738-2746 [1996]
  • Animal models of human disease . Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes
    135 ( 1 ) :39-61 [1989]
  • Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer
    14 ( 2 ) : R62 . [2012]
  • Akt forms an intracellular complex with heat shock protein 90 ( Hsp90 ) and Cdc37 and is destabilized by inhibitors of Hsp90 function
    277 ( 42 ) :39858-39866 . [2002]
  • Activity of the dual kinase inhibitor lapatinib ( GW572016 ) against HER2-overexpressing and trastuzumab-treated breast cancer cells
    66 ( 3 ) :1630-1639 . [2006]
  • A phase I study of the HSP90 inhibitor retaspimycin hydrochloride ( IPI-504 ) in patients with gastrointestinal stromal tumors or soft- tissue sarcomas .
    19 ( 21 ) :6020-6029 . [2013]
  • A phase I study of PF-04929113 ( SNX-5422 ) , an orally bioavailable heat shock protein 90 inhibitor , in patients with refractory solid tumor malignancies and lymphomas
    17 ( 21 ) :6831-6839 [2011]
  • A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    12 ( 4 ) :395-402 . [2007]
  • A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs
    43 ( 1 ) :13-18 . [1995]